A federal court dismissed ANH’s homeopathy lawsuit on procedural grounds—so we’re taking the fight directly back to the FDA.
Listen to the audio version of this article:
THE TOPLINE
- The court did not rule on the merits, dismissing the case instead for lack of standing.
- This leaves unresolved the core question of the FDA’s tightening restrictions on homeopathic medicines.
- ANH and Meditrend will file a new citizen petition within 30 days to press the case directly with FDA leadership.
On April 24, 2026, a federal court in Washington, D.C. dismissed ANH-USA and Meditrend’s lawsuit challenging the FDA’s crackdown on homeopathic medicines.
Importantly, the court did not rule on the merits—it never decided whether the FDA’s actions were lawful. Instead, the case was dismissed on a technical issue called “standing,” meaning the court found there wasn’t enough evidence directly linking the FDA’s specific actions to the harms claimed by the plaintiffs.
Speaking to these latest developments, ANH General Counsel Jonathan Emord said, “After holding standing present earlier in the case, the Judge did a volte face and ruled no standing present, doing so immediately before a decision on the merits of whether FDA acted in violation of the Administrative Procedure Act (APA). FDA did indeed violate the APA arbitrary and capricious decision-making standard when it presumed homeopathic drugs unsafe without requisite evidence. Because an appeal would add years to an already delayed decision on the merits, we are going back to FDA to demand the needed reforms, providing the reasons for, and the way to achieve, a reversal of the guidance FDA issued that revoked CPG 400.400 (the safe harbor for entry of homeopathic drugs into the market). We seek to reinstate CPG 400.400 as a first major step to save homeopathy in America.”
What This Means
This is not a ruling against homeopathy. It simply means the case couldn’t move forward in its current form. The bigger issue—how the FDA regulates homeopathic products—remains unresolved.
What ANH Is Doing Next
Rather than pursue a lengthy appeal that could take years and still avoid the core issues, ANH and Meditrend have decided on a more direct path: filing a new citizen petition with the FDA within the next 30 days.
This approach puts the issue directly in front of FDA leadership and offers a faster opportunity to challenge the agency’s current stance.
Bottom Line
This is a procedural setback, not the end of the road. ANH remains actively engaged in protecting access to homeopathic medicines and is moving quickly to press the case through new channels.
More updates soon.
